Avience Biomedicals IPO: Price Band, GMP, and Key Investment Details

Noida-based molecular diagnostics manufacturer Avience Biomedicals is set to launch its highly anticipated IPO this Thursday. With strong pre-listing demand reflected in the grey market, investors are closely monitoring this SME issue as it seeks to fund its next phase of manufacturing expansion.

IPO Pricing, Timeline, and Grey Market Buzz

The Avience Biomedicals IPO is priced in a band of Rs 196 to Rs 208 per share. The subscription window opens this Thursday and will remain active until June 22. Investors can expect the allotment process to be completed by June 23, with the company slated to list on the NSE SME platform on June 25.

Market sentiment appears bullish, as the Grey Market Premium (GMP) stands at approximately 36% ahead of the opening. This implies an unofficial market price of around Rs 283, representing a premium of roughly Rs 75 per share over the upper price band. This robust GMP signals strong investor appetite, setting it apart from other SME issues that have seen muted activity this week.

Issue Structure and Allocation Details

The total issue size is Rs 30.24 crore, consisting entirely of a fresh issue of 14,53,800 shares. Notably, there is no Offer-for-Sale (OFS) component, ensuring that the entire proceeds will be directed toward the company's growth initiatives. Out of the total issue, 13,71,600 shares are available to the public after reserving 82,200 shares for the market maker, Asnani Stock Broker.

The allocation is structured to favor institutional participation:

For retail investors, the lot size is fixed at 600 shares, requiring a minimum investment of Rs 1,24,800 at the upper price band. High-Net-Worth Individuals (HNIs) must apply for a minimum of 3 lots (1,800 shares), totaling approximately Rs 3,74,400.

Business Model and Financial Performance

A Avience Biomedicals é uma fabricante com certificação ISO, especializada em soluções de diagnóstico molecular, biotecnologia e genômica. Seu portfólio de produtos é diversificado, abrangendo desde kits de teste rápido para dengue e malária até analisadores bioquímicos e dispositivos médicos, como concentradores de oxigênio. A empresa opera em um modelo B2B e B2G, atendendo hospitais, laboratórios de patologia e centros de pesquisa, tanto na Índia quanto internacionalmente.

A empresa demonstrou um impulso financeiro significativo. A receita saltou de Rs 24,37 crore no AF24 para Rs 45,97 crore no AF25. Ainda mais impressionante é o crescimento do lucro líquido, com o Lucro Após Impostos (PAT) saltando de Rs 2,14 crore no AF24 para Rs 7,23 crore no AF25. Para os dez meses encerrados em janeiro de 2026, a empresa reportou uma receita total de Rs 41,94 crore e um PAT de Rs 5,74 crore.

Utilização dos Recursos

A empresa pretende utilizar o novo capital para reforçar suas capacidades de fabricação. Aproximadamente Rs 15,96 crore estão destinados a despesas de capital para a instalação de uma nova unidade de fabricação no Medical Device Park, sob a Yamuna Expressway Industrial Development Authority em Gautam Buddha Nagar, Uttar Pradesh. Um adicional de Rs 8,25 crore será destinado para atender às necessidades de capital de giro.

Principais Conclusões